Exploring the U.S. Regulatory Framework for Mobile Health
Exploring the U.S. Regulatory Framework for Mobile Health
Regulatory Affairs Software Solutions & Services Medical Devices In Vitro Diagnostics
Wednesday, 13 March 2024
QbD Group
Share
\
\
X (Twitter) 
\
\
LinkedIn 
\
\
WhatsApp 
\
\
Copy link 
\
\
Mail
The United States maintains a robust regulatory foundation for Digital Therapeutics (DTx), ensuring that they are supported by stringent regulatory measures, including clinical evidence and data protection management.
Every DTx requires mandatory approval from a health authority (HA) before hitting the market. Given the substantial market in the U.S. for prescribed DTx, this blog post delves into its regulatory landscape.
Play
Exploring the U.S. Regulatory Framework for Mobile Health | QbD Group
AI-generated audio
5:34
U.S. Basic Requirements for DTx Products
Subject to the U.S. Health Authority ( FDA) regulations, specifically under ‘ CFR Title 21 Subchapter H,’ DTx products are regulated similarly to medical devices, with classifications grounded on their intended use and associated risk levels.
This subchapter is parallel to the European Medical Device Regulation (EU) 2017/745. The majority of DTx applications are labeled as Class II medical devices under ‘ CFR Title 21 Subchapter H,’ necessitating a mandatory FDA pre-marketing submission.
While there is currently no CFR-specific regulation exclusively for DTx, the FDA division ‘Center for Devices and Radiological Health ( CDRH)’ adheres to the ‘CFR Title 21 Subchapter H’ for the approval process. A list of all FDA-cleared DTx products, along with other medical devices, is available to the public at Devices@FDA.
Notable Legalities to Keep in Mind:
-
The Health Insurance Portability and Accountability Act ensures the privacy and security of specific health information.
-
The Federal Trade Commission Act bars deceptive acts, including making false claims about apps’ safety or performance.
-
FTC’s Health Breach Notification Rule mandates certain businesses to notify following breaches of personal health record information.
If you’re planning to introduce your application to the U.S. market, exploring FDA digital health guidances (e.g., FDA Policy for Devices Software Functions and Mobile Medical Applications) can be beneficial.
The Emergence of the FDA’s Digital Health Center of Excellence
At the tail end of 2020, the FDA established the Digital Health Center of Excellence( DHCoE), aspiring to uplift all digital health stakeholders, including patients, innovators, manufacturers, healthcare providers, and even the FDA itself.
Currently, DHCoE offers advice and support for the FDA regulatory review of specific digital health technology and aids developers in transforming digital innovations into consumer-beneficial tools.
The DHCoE also strives to refine the FDA’s regulatory approach to Software as a Medical Device (SaMD), explore the potential of Artificial Intelligence and Machine Learning in SaMD, and ensure ongoing clarity for policy and regulation, while actively working towards international harmonization of digital health regulations. Adherence to the provided directives is pivotal.
Process Timelines and Costs (Level II):
- Marketing submission time frame: 6-12 months (varies based on the type of market submission)
- Estimated costs for marketing submission: Ranges from $3K for smaller businesses up to $113K for larger entities (dependent on the submission type)
Spotlight on U.S. Prescribed Digital Therapeutics (PDTx)
Prescribed Digital Therapeutics (PDTx) encapsulates digital therapeutic interventions that are prescribed by healthcare professionals, and are validated, evidence-based therapies tailored for the management or treatment of designated medical conditions. The first PDT was given the green light by the FDA at the close of 2017. As of April 2022, approximately 40 U.S. PDTx have gained clearance.
The Insurance Dynamic for DTx in the U.S.
The U.S. paints a unique picture in the Mobile Health landscape, primarily attributed to its Healthcare System. The absence of a singular, nationwide health insurance system implies there is no automatic link between a “cleared” App and national reimbursement.
Essentially, DTx companies are mandated to demonstrate quality performance, clinical compliance, and data protection, securing FDA approval prior to entry into the U.S. market. ( Source)
This reformulation attempts to maintain the original content and intent of the writer while enhancing the clarity and flow of the information. It separates distinct points into separate sections for improved readability and understanding. Let me know if further adjustments are needed!
Conclusion
The United States has made significant strides in the regulatory oversight of Digital Therapeutics (DTx). With a stringent foundation grounded in ‘CFR Title 21 Subchapter H’, the U.S. ensures that DTx products undergo rigorous evaluation similar to medical devices before entering the market. As DTx continues to evolve, it remains imperative for developers to be cognizant of various legalities, ranging from health information privacy to the veracity of app claims.
The establishment of the FDA’s Digital Health Center of Excellence (DHCoE) in 2020 marked a pivotal moment in the journey, aiming to streamline and enhance the regulatory processes while supporting the burgeoning digital health community. This has paved the way for innovations such as Prescribed Digital Therapeutics (PDTx), of which several have already received FDA approval.
However, the unique structure of the U.S. healthcare system poses challenges for DTx reimbursement. Companies must not only secure FDA clearance but also demonstrate their product’s efficacy, safety, and data protection integrity to navigate the intricate insurance landscape.
As the world of DTx continues to expand and evolve, staying abreast of the FDA’s regulatory framework is vital for those looking to make a mark in the U.S. digital health arena.
Want to stay up to date with all the latest developments and innovations in DtX? Subscribe to our newsletter.
Need regulatory support?
Trust our expertise to guide you through the regulatory process and achieve compliance
with ease.
Discover how we can help.
Stay ahead in life sciences
Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.
Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.
Discover more expert content
Webinar
From Strategy to First-in-Human: A Practical Roadmap for Biotech Development
Join our webinar to learn how to navigate nitrosamine risks and streamline your biotech development from early planning to first-in-human trials. Register now for expert insights.
Webinar
PMS & PMCF Compliance for Medical Devices Under EU MDR
Gain practical insights on PMS & PMCF compliance for medical devices under EU MDR. Watch our webinars on demand.
Case study
A Decade of Excellence: Linguistic Review Support for a Global Pharma Leader
QbD Group streamlines linguistic reviews for a leading pharma client, ensuring compliance and accuracy across 25 EU/EEA languages while meeting stringent regulatory deadlines.
Case study
Supporting Market Access to Essential Medicines in Europe
Support your entry into the European pharmaceutical market with expert regulatory guidance, ensuring compliance and access to essential medicines for patients. Contact us today for assistance.
%20Checklist.jpg)
Whitepaper
Medical Device Regulation (MDR) Checklist
Implement the Medical Device Regulation (MDR) with ease. Download our checklist of mandatory documents for MDR compliance.
Whitepaper
Regulatory Affairs for Pharma and Biotech
In this flyer, you will learn more about the regulatory services QbD Group provides for the pharmaceutical and biotechnology industries.
Whitepaper
Clinical Evaluation for Medical Devices under MDR
This whitepaper will guide you through crucial regulatory documents pertaining to the clinical evaluation process of your medical device. Download now!
Whitepaper
IVDR extension: what does this mean for you?
In this whitepaper, you will learn the impact of the IVDR transition extension and receive tips and strategies to navigate these regulatory changes.
Webinar
Drug-Device Combination Products and Article 117
Explore the regulatory complexities of Drug-Device Combination Products. Learn about Article 117 requirements, Notified Body Opinions, and more.
Whitepaper
Mobile health on the rise: exploring the regulatory landscape for reimbursement
This whitepaper will help you navigate the maze of the DTx regulatory environment, highlighting several important countries and regulations.
Whitepaper
Clinical investigations under MDR: key insights and practical experiences
This whitepaper covers clinical investigation authorization under MDR, the EU Legal Representative's role, and the MDR's impact on study conduct and post-market surveillance.
Case study
CE Mark Renewal for bioXtra Products: A Success Story
Discover how Lifestream Pharma successfully renewed the CE mark for their BioXtra Dry Mouth products under the EU MDR. Learn about the challenges faced, the approach taken for compliance, and the results achieved.
Webinar
Technical Documentation Essentials for Medical Device Software
Gain practical insights on crafting MDR-compliant technical documentation for Medical Device Software.
.jpg)
Webinar
Getting Started: Overcoming Initial Obstacles in Medical Device Software Development
Watch our webinar on demand and learn about regulatory obstacles, MDR, AI Act, and best practices for medical device software development and market entry.
Webinar
Mastering Clinical Performance Studies under IVDR
In the evolving regulatory landscape of IVDs, demonstrating clinical performance is more crucial and challenging than ever. Discover more in this webinar on demand.
Whitepaper
Clinical evidence for In Vitro Diagnostics under IVDR
In this whitepaper, we will guide you through the documents required for the demonstration of clinical evidence under the IVDR. Download now.
Webinar
Post-Market Surveillance Requirements for Medical Devices and IVDs
Learn about post-market surveillance requirements under MDR and IVDR regulations. Gain insights from industry experts in this on-demand webinar.
Whitepaper
The key role of Regulatory Affairs in the pharmaceutical industry: from drug development to commercialization
Discover the key role of Regulatory Affairs in pharma and how Regulatory Affairs teams support product lifecycle management in this whitepaper. Download now.
.jpg)
Webinar
3D Printing in the Healthcare World
Explore the challenges and opportunities of 3D printing in healthcare, featuring expert insights on regulations, pitfalls, and efficiency.
.jpg)
Webinar
IVDR Extension Explained: Tips & Strategies
Gain valuable insights on the IVDR extension and its impact on IVD manufacturers with our webinar on demand.
Whitepaper
Innovations in ATMP: state of the industry in 2024
This whitepaper explores the innovations in ATMP and solutions in detail, with a focus on the current landscape as of April 2024. Download now.
.jpg)
Case study
The journey toward IVDR compliance for the LVOne device
QbD Group helped Upfront Diagnostics gain entry into the MD/IVD industry by supporting them on their path to ISO 13485 certification.
Case study
Ensuring a smooth MDR transition for Oystershell's medical devices
The landscape of medical device regulations is constantly evolving, making it a challenge for companies to keep up. Our collaboration with Oystershell, which began in July 2023, highlights our expertise in transforming complex challenges into success stories, all with a touch of QbD Clinical magic.
Case study
Successful clinical evaluation supports rapid CE marking of Minze Health's Uroflowmeter
QbD Clinical assisted Minze Health, a urology-focused medical devices company, in obtaining CE marking under MDR through clinical evaluation.
.jpg)
Webinar
The Medical Device CE Certification Pathway Explained: From Classification to Conformity Assessment by the Notified Body
Learn about the Medical Device CE Certification Pathway, from classification to conformity assessment by a Notified Body. Join our webinar on demand.
.jpg)
Case study
Helping Relu to comply with changing regulations
QbD Group supported software company Relu with their expertise to comply with changing regulations.
.png)
Case study
Quickly bringing a new COVID-19 medical device to market
Obtaining the required government certifications for a medical device is always a challenge. Especially when the COVID clock is ticking.
Twitter Widget Iframe